Sunil Healthcare Ltd Stock Price Today (NSE: SUNLOC)
Fundamental Score
Sunil Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sunil Healthcare Ltd share price today is ₹61.97, down 3.68% on NSE/BSE as of 30 March 2026. Sunil Healthcare Ltd (SUNLOC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹74.32 (Cr). The 52-week high for SUNLOC share price is ₹88.70 and the 52-week low is ₹58.40. At a P/E ratio of 42.96x, SUNLOC is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -1.95% and a debt-to-equity ratio of 0.88.
Sunil Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sunil Healthcare Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sunil Healthcare Share Price Analysis: A ROCE-Focused Perspective
The pharmaceutical industry, while often perceived as recession-proof, faces increasing pressures on pricing and innovation. Generic drug manufacturers, like Sunil Healthcare Ltd, are particularly vulnerable to margin erosion. This analysis, part of an 80-parameter fundamental audit verified by Sweta Mishra, examines the financial health of Sunil Healthcare, focusing on its Return on Capital Employed (ROCE). Specifically, we'll examine how Sunil Healthcare share price is perceived against its peers. As of today, the Sunil Healthcare share price stands at ₹69.610001, with a Price-to-Earnings (PE) ratio of 42.96 and a ROCE of 3.96%.
The relatively high PE ratio suggests investors anticipate future growth. However, the ROCE, a crucial metric for evaluating capital efficiency, paints a less optimistic picture. A ROCE of 3.96% indicates that for every ₹100 of capital employed, Sunil Healthcare generates only ₹3.96 in earnings. This is significantly lower than what many investors would consider acceptable, especially when compared to other investment opportunities.
Comparing Sunil Healthcare Ltd to its peers reveals further insights. While a detailed analysis of
Mankind Pharma Ltd is beyond the scope of this focused report, differences in management quality and strategic direction between companies like Mankind Pharma and Sunil Healthcare can contribute to significant variances in ROCE and overall performance. A lower ROCE for Sunil Healthcare could be indicative of less efficient asset utilization, higher operating costs, or lower profit margins compared to its more successful competitors.The low ROCE has a direct impact on the company's economic moat, or its ability to maintain a competitive advantage. A strong moat allows a company to protect its profitability and generate sustainable returns. With a low ROCE, Sunil Healthcare struggles to reinvest earnings effectively and defend its market share. This makes it more susceptible to competition and less resilient to industry headwinds. Further investigation into the underlying drivers of the low ROCE is warranted to understand the long-term viability of the company.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sunil Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUNLOC across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (281.82%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (73.53%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-1.95%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 42.96x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (3.56% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.36x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.10%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sunil Healthcare Ltd Financial Statements
Comprehensive financial data for Sunil Healthcare Ltd including income statement, balance sheet and cash flow
About SUNLOC (Sunil Healthcare Ltd)
Sunil Healthcare Ltd. is a prominent manufacturer specializing in innovative capsule solutions for the pharmaceutical and nutraceutical industries, both within India and across int...ernational markets. They've carved a niche for themselves by focusing on the production of empty hard capsules, encompassing a wide range of materials to meet diverse customer needs. Their commitment to quality and adaptability is evident in their broad product portfolio. The company's expertise extends beyond standard gelatin capsules, embracing modern advancements in material science. Sunil Healthcare manufactures capsules from Hydroxypropyl Methylcellulose (HPMC), catering to the growing demand for vegetarian and vegan options. Furthermore, they produce pullulan capsules derived from tapioca, offering a naturally sourced alternative. This diversification allows them to serve a broader spectrum of pharmaceutical and health-conscious consumers. Beyond capsules, Sunil Healthcare ventures into the realm of traditional medicine, offering a range of Ayurvedic products based on time-tested herbs and formulations. They utilize ingredients such as turmeric, ginger, and ashwagandha. This complementary business demonstrates Sunil Healthcare's dedication to holistic wellness, blending modern pharmaceutical technology with ancient healing practices, reinforcing its commitment to health solutions.
Company Details
Key Leadership
SUNLOC Share Price: Frequently Asked Questions
What is the current share price of Sunil Healthcare Ltd (SUNLOC)?
As of 30 Mar 2026, 12:02 pm IST, Sunil Healthcare Ltd share price is ₹61.97. The SUNLOC stock has a market capitalisation of ₹74.32 (Cr) on NSE/BSE.
Is SUNLOC share price Overvalued or Undervalued?
SUNLOC share price is currently trading at a P/E ratio of 42.96x, compared to the industry average of 31.77x. Based on this relative valuation, the Sunil Healthcare Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SUNLOC share price?
The 52-week high of SUNLOC share price is ₹88.70 and the 52-week low is ₹58.40. These values are updated daily from NSE/BSE price data.
What factors affect the Sunil Healthcare Ltd share price?
Key factors influencing SUNLOC share price include quarterly earnings growth (Sales Growth: 16.09%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sunil Healthcare Ltd a good stock for long-term investment?
Sunil Healthcare Ltd shows a 5-year Profit Growth of 11.44% and an ROE of -1.95%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.88 before investing in SUNLOC shares.
How does Sunil Healthcare Ltd compare with its industry peers?
Sunil Healthcare Ltd competes with major peers in the Pharmaceuticals. Investors should compare SUNLOC share price P/E of 42.96x and ROE of -1.95% against the industry averages to determine competitive standing.
What is the P/E ratio of SUNLOC and what does it mean?
SUNLOC share price has a P/E ratio of 42.96x compared to the industry average of 31.77x. Investors pay ₹43 for every ₹1 of annual earnings.
How is SUNLOC performing according to Bull Run's analysis?
SUNLOC has a Bull Run fundamental score of 37.8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SUNLOC belong to?
SUNLOC operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sunil Healthcare Ltd share price.
What is Return on Equity (ROE) and why is it important for SUNLOC?
SUNLOC has an ROE of -1.95%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Sunil Healthcare Ltd generates profits from shareholders capital.
How is SUNLOC debt-to-equity ratio and what does it indicate?
SUNLOC has a debt-to-equity ratio of 0.88, which indicates moderate leverage that should be monitored.
What is SUNLOC dividend yield and is it a good dividend stock?
SUNLOC offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Sunil Healthcare Ltd shares.
How has SUNLOC share price grown over the past 5 years?
SUNLOC has achieved 5-year growth rates of: Sales Growth 3.56%, Profit Growth 11.44%, and EPS Growth 11.44%.
What is the promoter holding in SUNLOC and why does it matter?
Promoters hold 73.53% of SUNLOC shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sunil Healthcare Ltd.
What is SUNLOC market capitalisation category?
SUNLOC has a market capitalisation of ₹74 crores, placing it in the Small-cap category.
How volatile is SUNLOC stock?
SUNLOC has a beta of N/A. A beta > 1 suggests the Sunil Healthcare Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SUNLOC operating profit margin trend?
SUNLOC has a 5-year average Operating Profit Margin (OPM) of 10.84%, indicating the company's operational efficiency.
How is SUNLOC quarterly performance?
Recent quarterly performance shows Sunil Healthcare Ltd YoY Sales Growth of 16.09% and YoY Profit Growth of 281.82%.
What is the institutional holding pattern in SUNLOC?
SUNLOC has FII holding of 0.00% and DII holding of 0.10%. Significant institutional holding often suggests professional confidence in the Sunil Healthcare Ltd stock.